September 2021
-
Media ReleaseNovartis receives approval in Singapore for LEQVIO® (inclisiran), an innovative medication that changes the treatment paradigm for patients with high cholesterolLeqvio® (inclisiran) is an innovative medicine that can change how low-density lipoprotein cholesterol (LDL-C) or commonly known as bad cholesterol is treated.1, 2 Cardiovascular disease (CVD) is…
-
Story Discovery
Remote Patient Monitoring: The Unstoppable Wave of New Care Models – The Records -
In The NewsSingapore approves an innovative medication for patients with high cholesterolLeqvio® (inclisiran) is an innovative medicine that can change how low-density lipoprotein cholesterol (LDL-C) or commonly known as bad cholesterol is treated.
-
In The NewsCell therapy for relapsed cancer patientsSingapore has successfully treated its first patient using what is known as chimeric antigen receptor T-cell, or CAR-T therapy.
July 2021
-
In The NewsFactories: Making the FutureEver wondered what it's like inside some of Singapore's factories? This special feature documentary looks at cutting-edge products designed and manufactured in the city-state that will impact the way…
-
In The NewsMultinational pharmaceutical companies partner with local businesses to help economic recovery
March 2021
-
Media ReleaseNovartis receives approval for Kymriah® (tisagenlecleucel) by Health Sciences Authority as Singapore’s first commercially approved CAR-T therapyKymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy approved in Singapore, is indicated as a one-time treatment manufactured individually for each patient. Novartis works closely…
-
Media ReleaseNovartis Piqray® - First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approvalPiqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation The approval was based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median PFS…